Wynnefield Capital Inc. lowered its holdings in BioScrip Inc (NASDAQ:BIOS) by 1.0% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,030,925 shares of the company’s stock after selling 30,000 shares during the quarter. BioScrip accounts for 2.6% of Wynnefield Capital Inc.’s holdings, making the stock its 13th largest holding. Wynnefield Capital Inc. owned 2.37% of BioScrip worth $7,456,000 as of its most recent SEC filing.
Several other hedge funds have also recently bought and sold shares of BIOS. Gamco Investors INC. ET AL grew its holdings in shares of BioScrip by 4.0% in the 1st quarter. Gamco Investors INC. ET AL now owns 847,574 shares of the company’s stock worth $2,085,000 after acquiring an additional 32,500 shares during the period. BlackRock Inc. boosted its holdings in shares of BioScrip by 0.5% during the first quarter. BlackRock Inc. now owns 6,617,126 shares of the company’s stock worth $16,277,000 after purchasing an additional 33,021 shares during the last quarter. Gotham Asset Management LLC acquired a new stake in shares of BioScrip during the fourth quarter worth $114,000. Wells Fargo & Company MN boosted its holdings in shares of BioScrip by 34.4% during the fourth quarter. Wells Fargo & Company MN now owns 217,450 shares of the company’s stock worth $634,000 after purchasing an additional 55,636 shares during the last quarter. Finally, MetLife Investment Advisors LLC acquired a new stake in shares of BioScrip during the fourth quarter worth $174,000. Hedge funds and other institutional investors own 85.46% of the company’s stock.
BIOS has been the topic of several research reports. BidaskClub raised BioScrip from a “hold” rating to a “buy” rating in a research report on Saturday, March 3rd. Zacks Investment Research raised BioScrip from a “sell” rating to a “hold” rating in a research report on Tuesday, May 15th. SunTrust Banks reiterated a “buy” rating and issued a $3.25 price target on shares of BioScrip in a research note on Thursday, March 8th. Finally, Craig Hallum restated a “buy” rating and issued a $3.50 target price on shares of BioScrip in a research note on Thursday, March 8th. Two analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $3.44.
Shares of NASDAQ:BIOS opened at $2.93 on Friday. The company has a market cap of $376.18 million, a P/E ratio of -6.66 and a beta of 0.08. BioScrip Inc has a 12 month low of $1.80 and a 12 month high of $3.39. The company has a current ratio of 1.70, a quick ratio of 1.30 and a debt-to-equity ratio of -4.79.
BioScrip (NASDAQ:BIOS) last posted its quarterly earnings results on Thursday, May 10th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.11) by ($0.01). The business had revenue of $168.60 million during the quarter, compared to the consensus estimate of $164.72 million. During the same quarter in the prior year, the company earned ($0.18) earnings per share. The business’s quarterly revenue was down 22.6% compared to the same quarter last year. analysts anticipate that BioScrip Inc will post -0.31 earnings per share for the current fiscal year.
BioScrip, Inc provides infusion solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. The company is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care.
Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.